Novo Nordisk surges as Hims & Hers pulls copycat pill

Core Insights - The stock experienced significant movements, increasing by 5% on Friday and an additional 8% recently due to FDA signals regarding unauthorized compounded GLP-1 medications, which is crucial for Novonis amid tough competition [1] - Novonis has projected a sales decline of 5% to 13% in 2026, emphasizing the need to grow volume due to price erosion from competition [2] - The recently launched weight loss pill has been successful, with 90% of users opting for the smallest dosage, indicating new patient growth rather than cannibalization of existing treatments [3] - The first-mover advantage in the injection market is critical for Novonis, especially with competitors planning to launch their own pills later this year [4] - There was a previous supply issue with injections that allowed pharmacies to create compounded drugs, but this has since been resolved, impacting the market dynamics [5] - Approximately 1.5 million patients in the US are still using compounded injection drugs, indicating a slow process in regulating these products [6] - The CEO expressed confidence that supply issues will not affect the new pill, highlighting its importance in capturing market share before further competition arises [7]